Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption-Reference-Cited by-同舟云学术

Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption

Published:2005-09-15 Issue:6 Volume:41 Page:897-900
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clinical Infectious Diseases

Author:

Barreiro P.,de Mendoza C.,Gonzalez-Lahoz J.,Soriano V.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/41/6/897/5930830/41-6-897.pdf

Reference12 articles.

1. A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients

2. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

3. Meta-analysis of Two Randomized Controlled Trials Comparing Combined Zidovudine and Didanosine Therapy With Combined Zidovudine, Didanosine, and Nevirapine Therapy in Patients With HIV

4. Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by Nevirapine in Patients With Suppressed Plasma HIV-1 RNA

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergence of drug-resistance in HIV dynamics under distinct HAART regimes;Communications in Nonlinear Science and Numerical Simulation;2016-01

2. Piecewise HIV virus dynamic model with CD4+ T cell count-guided therapy: I;Journal of Theoretical Biology;2012-09

3. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART;AIDS;2009-04-27

4. Long-term HIV dynamics subject to continuous therapy and structured treatment interruptions;Chemical Engineering Science;2009-04

5. Nonnucleotide Reverse‐Transcriptase Inhibitors and Treatment Interruption;Clinical Infectious Diseases;2008-12-15